Search

Your search keyword '"Olsson, Anders G."' showing total 616 results

Search Constraints

Start Over You searched for: Author "Olsson, Anders G." Remove constraint Author: "Olsson, Anders G."
616 results on '"Olsson, Anders G."'

Search Results

1. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

2. RE: Praluent (Alirocumab)-Induced Renal Injury

3. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

4. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

5. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

7. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

8. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

10. Secretory Phospholipase A2-IIA and Cardiovascular Disease: A Mendelian Randomization Study

16. Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

23. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

26. Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

29. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia

35. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction

40. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

41. Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease

42. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial

49. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

50. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

Catalog

Books, media, physical & digital resources